General
Preferred name
ISONIAZID
Synonyms
PASINIAZID ()
Isoniazid54-85-3 ()
INH ()
Isonicotinic acid hydrazide ()
Isonicotinic hydrazide ()
pyridine-4-carbohydrazide ()
Eralon ()
Hidrasonil ()
Hydrazid ()
Ertuban ()
Ipcazide ()
Teebaconin ()
Mybasan ()
Laniazid ()
Nydrazid ()
Tisiodrazida ()
Hyzyd ()
Cedin ()
Isobicina ()
Nicotibine ()
Armazid ()
Isoniazid component of rifater ()
Armazide ()
Iscotin ()
Dow-Isoniazid ()
Isoniazid component of rifamate ()
Dianicotyl ()
Isonicotan ()
Rimifon ()
Isoniazida ()
Isoniazide ()
Atcotibine ()
Cotinazin ()
Isoniazidum ()
Neumandin ()
Stanozide ()
Isidrina ()
NSC-9659 ()
P&D ID
PD001926
CAS
54-85-3
37271-10-6
Tags
available
drug
Approved by
FDA
First approval
1952
Drug indication
Pulmonary tuberculosis
Tuberculosis
Drug Status
investigational
approved
Max Phase
4.0
Structure
Probe scores
P&D probe-likeness score
[[ v.score ]]%
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
PHARMACODYNAMICS Isoniazid is a bactericidal agent active against organisms of the genus Mycobacterium, specifically M. tuberculosis, M. bovis and M. kansasii. It is a highly specific agent, ineffective against other microorganisms. Isoniazid is bactericidal when mycobacteria grow rapidly and bacteriostatic when they grow slowly.
DESCRIPTION Isoniazid is an antimycobacterial drug used in the treatment of tuberculosis (TB) . Functionally, it inhibits the synthesis of mycolic acid, an essential component of the mycobacterial cell wall . (GtoPdb)
DESCRIPTION Isoniazid (INH) is a proagent and must be activated by a bacterial catalase-peroxidase enzyme KatG. Isoniazid is bactericidal to rapidly dividing mycobacteria and has anti-tuberculostatic activity[1][2][3][4].
PRICE 29
DESCRIPTION Isoniazid (Isonicotinic hydrazide) is an antibacterial agent used primarily as a tuberculostatic.
DESCRIPTION Isoniazid is an antibacterial agent used primarily as a tuberculostatic. It remains the treatment of choice for tuberculosis. At therapeutic levels isoniazid is bacteriocidal against actively growing intracellular and extracellular Mycobacterium tuberculosis organisms. Specifically isoniazid inhibits InhA, the enoyl reductase from Mycobacterium tuberculosis, by forming a covalent adduct with the NAD cofactor. (Enamine Bioactive Compounds)
DESCRIPTION Inhibition of Mycobacterium tuberculosis dihydrofolate reductase (TargetMol Bioactive Compound Library)
Cell lines
3
Organisms
3
Compound Sets
26
Cayman Chemical Bioactives
20378
CeMM library of unique drugs (CLOUD)
ChEMBL Approved Drugs
CHEMBL64
ChEMBL Drugs
CHEMBL64
CZ-OPENSCREEN Bioactive Library
Drug Repurposing Hub
DrugBank
DB00951
DrugBank Approved Drugs
DB00951
DrugCentral
1497
DrugCentral Approved Drugs
1497
DrugMAP
DM5JVS3
DrugMAP Approved Drugs
DM5JVS3
DrugMatrix
Enamine Bioactive Compounds
EBC-11047
Enamine BioReference Compounds
Guide to Pharmacology
12761
MedChem Express Bioactive Compound Library
HY-B0329
NCATS Inxight Approved Drugs
V83O1VOZ8L
NIH Clinical Collections (NCC)
NPC Screening Collection
Pandemic Response Box
Prestwick Chemical Library
ReFrame library
Selleckchem Bioactive Compound Library
Isoniazid(Tubizid)
TargetMol Bioactive Compound Library
0272-0055
The Spectrum Collection
External IDs
56
Properties
(calculated by RDKit )
Molecular Weight
137.06
Hydrogen Bond Acceptors
3
Hydrogen Bond Donors
2
Rotatable Bonds
1
Ring Count
1
Aromatic Ring Count
1
cLogP
-0.31
TPSA
68.01
Fraction CSP3
0.0
Chiral centers
0.0
Largest ring
6.0
QED
0.32
Structural alerts
0
No structural alerts detected
Related compounds
Custom attributes
(extracted from source data)
MOA
bacterial InhA inhibitor
FABI inhibitor
Target
Enoyl-[acyl-carrier-protein] reductase
CYP1A2, CYP2C19, CYP2C8, CYP2E1, CYP3A4
antibiotic
Autophagy
Bacterial
Mitophagy
Fatty acid synthase
Indication
tuberculosis
Therapeutic Class
Antitubercular Agents
Pathway
Anti-infection
Source data